VivoSeq
Oncology

B-Cell Non-Hodgkins Lymphoma

22

Pipeline Programs↗

1

Active Trials↗

15

Companies Involved↗

B-cell non-Hodgkins lymphoma is an emerging landscape with 22 programs across 15 companies. The most active players are Bristol-Myers Squibb, Gilead, Teva. 5 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

47/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 1Gilead logo

Gilead

1 program

Phase 1Teva logo

Teva

2 programs

Phase 2Pfizer logo

Pfizer

1 program

Phase 2A

Avyxa

1 program

Phase 2Johnson & Johnson logo

Johnson & Johnson

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

22programs
Small molecule1359%
Monoclonal antibody732%
Antibody–drug conjugate29%

Modality classified for 100% of 22 pipeline programs.

Analysis

Trial Status

4

clinical trials

Completed3 · 75%
Recruiting1 · 25%

Clinical Trials

Trial Activity

Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Completed·—·Phase 2·NCT00577629·39 enrolled
Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma
Completed·Bristol-Myers Squibb logoBristol-Myers Squibb·Phase 1·NCT01775631·47 enrolled
A Study of Escalating Doses of Polatuzumab Vedotin in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia and Polatuzumab Vedotin in Combination With Rituximab in Participants With Relapsed or Refractory B-Cell Non-Hodgkins Lymphoma
Completed·Roche logoRoche·Phase 1·NCT01290549·95 enrolled
A Phase II, Open-Label, Multicenter Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Patients With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Recruiting·Roche logoRoche·Phase 2·NCT06806033·100 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)